THOUSAND OAKS, Calif.,
July 30, 2015 /PRNewswire/
-- Amgen (NASDAQ: AMGN) today announced the appointment of
Fred Hassan, partner and managing
director of Warburg Pincus LLC, to the Amgen Board of
Directors.
"We are pleased to welcome Fred
Hassan and the deep, global experience he brings in the
biopharmaceuticals sector to the Amgen Board," said Robert A. Bradway, chairman and chief executive
officer of Amgen. "Fred's breadth of operational expertise and
commitment to innovation will serve Amgen well."
Mr. Hassan has been Partner and Managing Director at Warburg
Pincus LLC, a global private equity investment institution, since
2011 and, prior to that, served as Senior Advisor from 2009 to
2010. Mr. Hassan was Chairman of the Board and Chief Executive
Officer of Schering-Plough Corporation from 2003 to 2009. Prior to
this, Mr. Hassan was Chairman, President and Chief Executive
Officer of Pharmacia Corporation, from 2001 to 2003. Before
assuming these roles, he had served as President and Chief
Executive Officer of Pharmacia Corporation from its creation in
2000 as a result of the merger of Pharmacia & Upjohn, Inc. with
Monsanto Company. He was President and Chief Executive
Officer of Pharmacia & Upjohn, Inc. beginning in 1997.
Mr. Hassan previously held senior positions with Wyeth (formerly
known as American Home Products), including that of Executive Vice
President with responsibility for its pharmaceutical and medical
products businesses, and served as a member of the board from 1995
to 1997. Prior to that, Mr. Hassan held various roles at
Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals
businesses.
Mr. Hassan has been a director of Time Warner Inc., a media
company, since 2009. Mr. Hassan was a director of Avon
Products, Inc., a manufacturer and marketer of beauty and related
products, from 1999 until 2013 and served as lead independent
director from 2009 to 2012 and Chairman of the Board between
January and April 2013. Mr. Hassan was Chairman of the Board
of Bausch & Lomb, from 2010 until its acquisition by Valeant
Pharmaceuticals International, Inc., a pharmaceutical company, in
2013. Mr. Hassan served on the board of directors of Valeant
Pharmaceuticals International, Inc. between August 2013 and May
2014.
Mr. Hassan's book, "Reinvent - A Leader's Playbook for Serial
Success," was published in 2013 by Wiley and describes the linkage
between attitude, culture, execution and driven
performance. In 2014, a CNBC panel named Mr. Hassan to a
list of those who have had the most profound impact on the world of
business in the previous quarter century.
Mr. Hassan will serve on the Audit Committee and the
Compensation and Management Development Committee of the Board.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008
(media)
Trish Hawkins, 805-447-5631
(media)
Arvind Sood, 805-447-1060
(investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-appointment-of-fred-hassan-to-board-of-directors-300121507.html
SOURCE Amgen